Advertisement
AXSM vs MMIRF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and MMIRF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXSM’s FA Score shows that 0 FA rating(s) are green whileMMIRF’s FA Score has 0 green FA rating(s).
- AXSM’s FA Score: 0 green, 5 red.
- MMIRF’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXSM’s TA Score shows that 5 TA indicator(s) are bullish while MMIRF’s TA Score has 4 bullish TA indicator(s).
- AXSM’s TA Score: 5 bullish, 4 bearish.
- MMIRF’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXSM (@Biotechnology) experienced а +3.58% price change this week, while MMIRF (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.
Reported Earning Dates
AXSM is expected to report earnings on Nov 10, 2025.
Industries' Descriptions
@Biotechnology (+4.31% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXSM | MMIRF | AXSM / MMIRF | |
| Capitalization | 5.9B | 40.7M | 14,491% |
| EBITDA | -230.81M | -3.24M | 7,133% |
| Gain YTD | 39.688 | 587.023 | 7% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 495M | 254K | 194,882% |
| Total Cash | 303M | 18.3K | 1,655,738% |
| Total Debt | 217M | 10.2M | 2,127% |
AXSM | MMIRF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 62 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 52 | 34 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MMIRF's Valuation (36) in the null industry is somewhat better than the same rating for AXSM (90) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew somewhat faster than AXSM’s over the last 12 months.
AXSM's Profit vs Risk Rating (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for MMIRF (100) in the null industry. This means that AXSM’s stock grew somewhat faster than MMIRF’s over the last 12 months.
AXSM's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that AXSM’s stock grew similarly to MMIRF’s over the last 12 months.
MMIRF's Price Growth Rating (34) in the null industry is in the same range as AXSM (52) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to AXSM’s over the last 12 months.
MMIRF's P/E Growth Rating (100) in the null industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to AXSM’s over the last 12 months.
| AXSM | MMIRF | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 61% |
| Advances ODDS (%) | 1 day ago 78% | N/A |
| Declines ODDS (%) | 9 days ago 81% | N/A |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 80% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VCRCX | 14.57 | 0.10 | +0.69% |
| NYLI CBRE Global Infrastructure Class C | |||
| ICRNX | 10.14 | 0.05 | +0.50% |
| VY® CBRE Global Real Estate A | |||
| RWMAX | 65.93 | -0.01 | -0.02% |
| American Funds Washington Mutual R1 | |||
| HRSRX | 85.90 | -0.21 | -0.24% |
| Hood River Small-Cap Growth Investor | |||
| CFSLX | 11.81 | -0.03 | -0.25% |
| Column Small Cap | |||
AXSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with PLRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then PLRX could also see price increases.
| Ticker / NAME | Correlation To AXSM | 1D Price Change % | ||
|---|---|---|---|---|
| AXSM | 100% | +0.60% | ||
| PLRX - AXSM | 39% Loosely correlated | -2.67% | ||
| CRNX - AXSM | 38% Loosely correlated | +6.35% | ||
| ALNY - AXSM | 38% Loosely correlated | -0.98% | ||
| XENE - AXSM | 36% Loosely correlated | -0.11% | ||
| FULC - AXSM | 35% Loosely correlated | -1.34% | ||
More | ||||
MMIRF and
Correlation & Price change
A.I.dvisor tells us that MMIRF and SGMT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and SGMT's prices will move in lockstep.
| Ticker / NAME | Correlation To MMIRF | 1D Price Change % | ||
|---|---|---|---|---|
| MMIRF | 100% | N/A | ||
| SGMT - MMIRF | 32% Poorly correlated | -1.17% | ||
| NWPHF - MMIRF | 29% Poorly correlated | N/A | ||
| VTYX - MMIRF | 26% Poorly correlated | -1.06% | ||
| AXSM - MMIRF | 21% Poorly correlated | +0.60% | ||
| DNTH - MMIRF | 21% Poorly correlated | +0.29% | ||
More | ||||